Some breast cancer patients remain at risk for developing lymphedema well after their cancer treatment is concluded and should be monitored a minimum of three years, according to data published in the Annals of Surgical Oncology.
Lymphedema, a disabling swelling that is a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society, 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema. Additionally, over 80% of breast cancer patients can be at risk based on the type of cancer treatment they have received.
https://www.impedimed.com/stopping-lymphedema-starts-with-prevent/
